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Abstract Primary treatment of rectal cancer was the focus of the second St. Gallen European
Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Con-
ference. In the context of the conference, a multidisciplinary international expert panel dis-
cussed and voted on controversial issues which could not be easily answered using
published evidence. Main topics included optimal pretherapeutic imaging, indication and type
of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report
the key recommendations and summarise the related evidence. The treatment strategy for lo-
calised rectal cancer varies from local excision in early tumours to neoadjuvant radioche-
motherapy (RCT) in combination with extended surgery in locally advanced disease.
Optimal pretherapeutic staging is a key to any treatment decision. The panel recommended
magnetic resonance imaging (MRI) or MRI þ endoscopic ultrasonography (EUS) as manda-
tory staging modalities, except for early T1 cancers with an option for local excision, where
EUS in addition to MRI was considered to be most important because of its superior near-
field resolution. Primary surgery with total mesorectal excision was recommended by most pa-
nellists for some early tumours with limited risk of recurrence (i.e. cT1-2 or cT3a N0 with clear
mesorectal fascia on MRI and clearly above the levator muscles), whereas all other stages were
considered for multimodal treatment. The consensus panel recommended long-course RCT
over short-course radiotherapy for most clinical situations where neoadjuvant treatment is
indicated, with the exception of T3a/b N0 tumours where short-course radiotherapy or even
no neoadjuvant therapy were regarded to be an option. In patients with potentially resectable
tumours and synchronous liver metastases, most panel members did not see an indication to
start with classical fluoropyrimidine-based RCT but rather favoured preoperative short-course
radiotherapy with systemic combination chemotherapy or alternatively a liver-first resection
approach in resectable metastases, which both allow optimal systemic therapy for the metasta-
tic disease. In general, proper patient selection and discussion in an experienced multidisci-
plinary team was considered as crucial component of care.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The second St. Gallen European Organisation for
Research and Treatment of Cancer (EORTC) Gastro-
intestinal Cancer Conference 2014 focussed on the pri-
mary treatment of rectal cancer. A representative faculty
of expert surgeons, radiation oncologists and medical
oncologists, pathologists and gastroenterologists
reviewed the current knowledge and discussed treatment
recommendations in a panel session based on a
moderated consensus process. The main interests were
controversial issues which could not be easily answered
through study of published evidence and guidelines
[1e4]. As in the St. Gallen Breast Cancer Conferences,
the panel was asked to assess the available evidence and
vote on recommendations using a precirculated set of
questions. A detailed review of the presentations has
been published elsewhere [5]. Here, we summarise the
key discussion points of the panel members.
The treatment strategy for localised rectal cancer is
based on clinical examination together with endoscopy
and imaging using either magnetic resonance imaging
(MRI) and/or endoscopic ultrasonography (EUS) and is
currently guided mainly by the risk of local recurrence,
e.g. European Society for Medical Oncology (ESMO) [1]
or the National Comprehensive Cancer Network
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(NCCN) guidelines [4]. The most important aim is the
prevention of recurrent disease with as little treatment-
related morbidity as possible and with maintained
bowel, sexual and genitourinary function. Treatment
options vary from organ-preserving local excision in
very early tumours to a combination of radio-
chemotherapy (RCT) with extended surgery in locally
advanced disease. If the risk of recurrence or lymphatic
invasion is low (i.e. in cT1 sm1 tumours without nodal
involvement and without unfavorable prognostic factors
like poor differentiation or venous invasion), local
excision may be sufficient. Primary extended surgery
with total mesorectal excision (TME) is discussed for
early tumours with limited risk of recurrence (i.e. mrT1-
2 or mrT3a spread <5 mm, mrEMVI negative with clear
TME plane), whereas all other substages are commonly
considered for multimodal treatment. In any case,
optimal pretherapeutic staging is essential for any
treatment decision.
There is an ongoing debate on the ideal modality and
sequence of combination treatment for intermediate
stages. Influencing factors are depth of extramural
spread, the distance from the anal verge, the circum-
ferential location, the distance of the tumours from the
mesorectal fascia, and the involvement of extramural
vessels (extramural vascular invasion [EMVI]) or nerves.
This uncertainty may be exemplified in T3b or less
tumours in the upper or middle rectum, which have a
low risk of local failure, if the tumour is >1 mm from
the mesorectal fascia (MRF). For these stages, the
ESMO guidelines consider primary surgery followed by
adjuvant treatment if judged necessary after patholog-
ical evaluation [1], whereas the NCCN guidelines favour
preoperative chemotherapy or preoperative combined
RCT and recommend adjuvant treatment for all pa-
tients [4].
The choice and sequence of multimodal treatment
combinations was another topic. In general, preopera-
tive treatment is preferred because it is less toxic and
more effective in local control than adjuvant treatment.
Accepted standards for the preoperative approach are
either the use of a short course of radiotherapy (SCRT)
over 5 d followed by immediate surgery or the combi-
nation of fluoropyrimidine-based chemotherapy with a
long course of conventionally fractioned RCT followed
by surgery after 6e8 weeks. Compliance and immediate
toxicity are in favour of SCRT, whereas RCT has the
potential of downsizing and downstaging of tumours. In
contrast, the standards for postoperative treatment are
less well defined. Adjuvant chemotherapy (ACT) is
performed in many patients who had already received
preoperative RCT, even though the evidence is limited.
Postoperative RCT is recommended for all pT3/T4 and/
or pNþ tumours which had not been treated preoper-
atively, a recommendation which may not hold in
limited disease (i.e. T3 tumours) or in tumours of the
upper rectum.
2. Methods
In preparation for the panel session, which was held on
8th March 2014 with 27 experts, existing guidelines were
used to identify areas of uncertainty in order to define
the topics for debate. Over 100 questions were circulated
between panel members, of which 42 were retained for
the joint discussion. During the session, the panel
members were asked to assess and comment on the
existing data and to recommend treatment strategies as
expert opinion. Panel members were given the oppor-
tunity to comment on the questions, before and after an
electronic vote. Here, we summarise the extent of
agreement or disagreement of the panel members.
Even though care was taken to invite a representative
spectrum of panellists from relevant disciplines, the gen-
eral applicability of their conclusions may be limited by
an unequal distribution of disciplines and/or
underrepresentation of some regions of the world. In
addition, generalised treatment recommendations
depend also on patient selection. The statements to follow
are usually meant for reasonably fit patients with no
relevant comorbidities. Many patients in clinical practice
will not match the hypothetical model and treatment
decisions will need to be made on an individual basis.
3. Pretherapeutic local staging
Accurate pretherapeutic imaging of the tumour and
lymph nodes is the key component of any treatment
decision, in addition to clinical examination, endoscopy
and screening for distant metastases. The vast majority
of the expert panel members considered the inclusion of
MRI (91% of the panellists) or even MRI þ EUS (33%)
as mandatory for ‘local imaging of the tumour’ with no
role for EUS or computed tomography (CT) scans
alone. Sole exceptions are T1 tumours where organ-
sparing surgery or endoscopic en-bloc resection is
considered as a potential treatment option. There, EUS
was recommended by 88% of the panellists because of its
excellent resolution and its superior definition of the
infiltration depth, with 38% opting for additional MRI.
To detect ‘lymph node involvement’, MRI was also
considered to be the best imaging tool (92% for MRI
alone, 8% together with EUS). The validated parameters
using MRI are irregularity of the border and mixed
signal intensity [6,7]. Using ultrasound, the roundness,
echogenicity, and imaging pattern (architecture) have
been described.
Several meta-analyses or systematic reviews exam-
ined the quality of T and N staging with various imaging
techniques. Summary results of the largest series are
listed in Table 1. However, the meta-analyses incorpo-
rating such a wide range of imaging standards must be
interpreted with caution as many of the older and larger
studies included used low-resolution techniques and
undefined diagnostic assessment criteria.
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Overall, an acceptable accuracy was demonstrated
for all three imaging modalities. In a meta-analysis
reviewing nonehigh-resolution techniques and older
MRI studies, EUS performed significantly better for the
definition of ‘invasion into the muscularis propria’, i.e.
for the distinction of T1 and T2 tumours, where its
specificity reached 86% (95% confidence interval [CI]:
80e90%) compared with 69% (95% CI: 52e82%) for
MRI [8]. The sensitivity was high in both groups (94%),
indicating a greater potential for overstaging with MRI
when using older low-resolution techniques and impre-
cise definitions of assessment of tumour spread [8].
However, the modern high-resolution techniques have
proven MRI to assess depth of spread accurately to
within 1 mm of histopathology assessments [9]. The use
of MRI in selecting patients for local excision rather
than TME surgery now hinges on the assessment for the
degree of preservation of the muscularis and submucosal
layers which enable a judgement of the safety of the
excision planes [5]. CT imaging was not compared
because of the insufficient resolution of the layers of the
rectal wall.
Results for lymph node involvement were compara-
ble for all three modalities with low-sensitivity rates
(55e69%). However, EUS can technically only be used
to evaluate the perirectal lymph nodes, whereas MRI
using high-resolution techniques identifies disease within
the entire mesorectum and pelvic sidewall compartment.
Based on the morphologic criteria of mixed signal in-
tensity and irregularity of the nodal border rather than
size criteria, the prevalence of pelvic sidewall metastatic
disease is 11%, and MRI detection of patients with
pelvic sidewall nodal disease is associated with poorer
overall disease-free survival (DFS) unless RCT is given
[9]. CT is used to examine the regional lymph nodes in
the pelvis and retroperitoneum. The accuracy is related
to T-stage and increases with lymph node size [10]. In a
series of EUS-staged rectal cancer, lymph node metas-
tases of increasing size were observed in the resection
specimen in 29% of pT1 tumours (median size of
3.3 mm), in 30% of pT2 tumours (median size of
6.2 mm), and in 46% of pT3 tumours (median size of
8.0 mm) with resulting accuracies of preoperative im-
aging of 48% in pT1, 67% in pT2, and 84% in pT3.
Measuring only the size of lymph nodes leads to sub-
stantial overstaging because benign reactive nodes are
seen in many patients and can enlarge to any size [11].
Nodal heterogeneity or penetration of the outer rim
which results in border irregularity in high-resolution
images are well-known features of malignancy [6,12,13]
which may be used as additional parameters if there is
sufficient imaging resolution in larger nodes.
MRI will depict lymph nodes with high sensitivity
and the majority of benign reactive nodes will be
positioned close to the mesorectal fascia posteriorly.
However, audit of specimens has shown that lymph
nodes are an extremely rare cause of circumferential
resection margin (CRM) involvement occurring in
<1.3% of patients and, therefore, caution should be
exerted when recommending neoadjuvant therapy solely
because an encapsulated lymph node is visualised close
to the mesorectal fascia [12]. Both EUS and CT are
unable to identify the mesorectal fascia [8]. Optimised
MRI performed according to standardised protocols by
trained investigators is able to predict the extent of
tumour outside the muscularis propria within a toler-
ance of 0.5 mm and correctly predicted a clear CRM in
94% in the MERCURY trial [14], with 1 mm as best
cut-off distance for predicting CRM involvement [15].
Follow-up data indicate that MRI-based pretherapeutic
definition of an involved CRM is an independent
prognostic factor for 5-year overall survival (62.2% in
Table 1
Pooled estimates of sensitivities and specificities of the routinely used imaging modalities for local staging of rectal cancer.
T Staging N Staging
MRI [74]
Systematic review
and meta-analysis,
22 studies
T category CRM involvement N
Sensitivity Specificity Sensitivity Specificity Specificity Sensitivity
87 (81e92) 75 (68e80) 77 (57e90) 94 (88e97) 71 (58e81) 77 (69
EUS [75]
Systematic Review,
42 studies, NZ 5,039
T2 T3 T4
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
81 (78e83) 96 (95e96) 96 (95e97) 91 (90e92) 95 (92e98) 98 (98e99)
EUS versus MRI versus
1CT [8] Meta-analysis,
90 studies
T2
‘muscularis propria
invasion’
T3
‘perirectal tissue invasion’
T4
‘adjacent organ
involvement’
N
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
EUS 94 (90e97) 86 (80e90) 90 (88e92) 75 (69e81) 67 (70e73) 78 (71e84) 67 (60e73) 78 (71e84)
MR 94( 89e97) 69 (52e82) 82 (74e87) 76 (65e84) 66 (54e76) 76 (59e87) 66 (54e76) 76 (59e87)
CT e e 79 (74e84) 78 (73e83) 55 (43e67) 74 (67e80) 55 (43e67) 74 (67e80)
Values are expressed in % with 95% confidence interval in brackets.
CRM, circumferential resection margin; CT, computed tomography; EUS, endoscopic ultrasonography; MRI, magnetic resonance imaging.
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MRI-CRM clear as compared to 42.2% in CRM
involved), for DFS (67.2% versus 47.3%) and for local
recurrence with a hazard ratio of 3.5 (95% CI of
1.53e8.0, p < 0.05). MRI-defined EMVI is an addi-
tional independent poor prognostic factor for both local
recurrence and for DFS in stage II/III rectal cancer [16].
Examples for a minimum technical requirements and
reporting are given in Table 2.
4. Do T3 rectal cancers always need RCT or
radiotherapy?
Preoperative chemoradiation (RCT) or short-course
preoperative radiotherapy (SCRT) are considered stan-
dard of care for patients with clinical stage II and III
rectal cancer because of the risk of local recurrence with
surgery alone and because of the postulated potential
for sphincter preservation. Many multidisciplinary
teams advocate SCRT or RCT for all patients with
rectal cancer staged as cT3 regardless of nodal status,
tumour location, and proximity to other structures or
extent. However, omitting RCT or SCRT would offer
the benefit of improved wound healing, less frequent
anastomotic leaks, avoidance of long-term radiation
toxicity, and a smaller risk of secondary malignancies
[17e21].
The ‘site of the primary tumour location and the
presence of lymph node metastases’ appear crucial to
decision making. The consensus panel was asked to
choose the optimal preoperative treatment (SCRT,
RCT, or primary surgery with no additional multimodal
therapy) for three different clinical situations. For units
where quality-controlled TME is done, and for easily
resectable cancers of the mid-rectum with no detectable
lymph node metastases (cT3 cN0), 71% of panellists did
not feel combination treatment was required for all
patients, but 25% did, albeit there was some debate as to
the definition of ‘easily resectable’, which may be defined
as tumours with less than 5 mm infiltration depth into
the mesorectal fat and at least 1 mm distance from the
mesorectal fascia (see also Table 3). In contrast, for cT3
cN0 low rectal cancer, 66% voted that SCRT or RCT
were necessary. The majority of the panellists also
considered RCT the best option for treating easily
resectable rectal cancer of the mid-rectum with lymph
node metastases (cT3 cNþ). Only 20% voted that neo-
adjuvant treatment was not required, and 75% of the
panellists considered SCRT to be an appropriate alter-
native option in this situation. In the interval, data have
emerged from the multicentre MERCURY 2 trial which
has shown that almost half of patients with tumours
arising <6 cm from the anal verge when staged by MRI
Table 2
Minimum technical requirements for MRI and its interpretation and reporting in pretherapeutic staging of rectal cancer [76].
MRI staging of rectal cancer
Technical requirement
- 1.5 or 3 Tesla system with phase array coil
- Standard T2 fast-spin echo for initial localisation/planning
- High-resolution T2-weighed images: minimal voxel density of 1.1 mm3, e.g. 3-mm sections with in-plane resolution of 0.5e0.8 mm
Scanning protocol
- Sagittal T2-weighted fast-spin echo to identify the tumour
- Large field-view axial sections of the whole pelvis
- High-resolution axial images of the tumour and adjacent tissues (perpendicular to the rectum long axis at the tumour level)
- Lymph node assessment: high-resolution axial imaging of the upper tumour border up to L5/S1
- Low tumours: high-resolution coronal imaging of levator muscles, sphincter complex and their relation to the rectal wall
- Sessile lesions/polyps: high-resolution sagittal series
Interpretation and reporting
- Technique, resolution, quality
- Height of the tumour (from the anal verge)
- Tumour description
 Size
 Circumferential location
 T-stage
 Infiltration depth beyond muscularis propria (mm)
- Nodal spread
 Location (perirectal, pelvic)
 Number
 Description (size, signal intensity, irregular border)
 Distance from tumour and MRF
- Extramural vascular invasion
- CRM status (distance to MRF < 1 mm?)
CRM, circumferential resection margin; MRI, magnetic resonance imaging.
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are not invading the distal TME/intersphincteric plane.
Rectal cancers localised in the upper third of the rectum
were exempt from the discussion as they are usually
treated by analogy with colon cancer.
A large majority of panellists believe RCT to be
required if clinical staging suggests the status is ‘cNþ’.
Also, when MRI shows a ‘threatened/breached CRM’
(10e15% of cases), or in cancers which require surgical
resection beyond the conventional TME and in clinically
unresectable cancers, downstaging is required and RCT
was considered the modality of choice [22]. As a
consequence, 66% of the panellists considered it neces-
sary to distinguish between patients with MRI criteria
which predict a high risk of local recurrence versus those
with a high risk of metastases (i.e. EMVI) and tailor
treatment appropriately.
The results from the Dutch TME trial [23] show a
marginal benefit for SCRT in stage II (N0) patients
(local recurrence [LR], 5.3% versus 7.2%), arguing
against any preoperative therapy, but the MRC CR07
trial [24] demonstrated a reduction of LR from 6.4% to
1.9%, again with SCRT. However, none of these trials
nor any of the chemoradiation trials published in the
last decade have shown any difference in overall survival
[25e28]. None of these trials used modern MRI staging
techniques to assess CRM, mrEMVI status or depth of
tumour spread beyond the muscularis propria. Norwe-
gian population data suggested low rates of local
recurrence for patients with pathological findings of a
clear CRM >3 mm and pN0 [29]. Several groups, which
are known to perform high-quality surgery, have
recently explored omitting radiotherapy when MRI
suggests the tumour is easily resectable and the meso-
rectal fascia is not threatened regardless of nodal stage.
This omission is associated with the local recurrence
rates of <5% [30e33].
The ‘quality of surgery’ is crucial. The majority of
local recurrences historically reflected inadequate mes-
orectal resection [34], which is a common finding on
postoperative MRI after partial mesorectal excision [35].
Careful dissection particularly in the posterior aspect of
a TME specimen with its higher prevalence of lymph
nodes is important [36]. Currently, optimal quality-
controlled surgery in terms of TME in the trial setting
can be associated with local recurrence rates of less than
10% whether patients receive radiotherapy or not [37].
Table 3
Proposed mid-rectal cancer risk categorisation based on MRI and clinical risk factors.
Risk stratification for cancer of the mid rectum
Low risk Intermediate risk High risk
Low-risk local recurrence/
low-risk metastases
Low-risk local recurrence/
moderate-risk metastases
Moderate-risk of local
recurrence/high-risk
metastases
High risk of local
recurrence/higher risk
metastases
High-risk local recurrence/
high-risk metastases
MRI cT2/T3a/T3b, <4 mm
extension into muscularis
propria, CRM not
threatened (predicted
>2 mm), cN0, CT M0
MRI cT3b, >4 mm
extension into muscularis
propria, CRM not
threatened (predicted
>2 mm), cN1, CT M0
MRI cT3b, >4 mm
cT3c, cN2, EMVI,
CRM not threatened
(predicted >2 mm), CT
M0
MRI cT3d, T4a
(resectable), CRM not
threatened (predicted
>2 mm), CT M0
MRI cTany, extension into
muscularis propria, T4b, CRM
breached or threatened
(predicted <1 mm), CT M0
Possibly Mucinous
Potential MRI-directed recommendations
No requirement for preop
radiotherapy
Immediate surgery
If surgeon convinced able to
perform R0 resection and
good quality in mesorectal
plane could omit RT
SCRT depending on
whether shrinkage of
tumour required or
neoadjuvant
chemotherapy alone
SCRT or RCT depending
on whether shrinkage of
tumour required or
neoadjuvant
chemotherapy alone
Requires RCT
Clinical risk factors
- Obesity
- Male/with anterior tumours
- Narrow pelvis
- Previous pelvic surgery
- Large bulky tumour
- Sepsis/fistula/perforation
UK NICE Guidelines and Recommendations
Low risk þ (but does not
include T3b < 4 mm)
Any cT3b or greater, in which the potential surgical margin is not
threatened or
Any suspicious lymph node not threatening the surgical resection
margin or
The presence of extramural vascular invasion
Threatened (<1 mm) or breached
resection margin or low tumours
encroaching onto inter-
sphincteric plane or levator
involvement
Do not give RT SCRT or RCT RCT recommended
CRM, circumferential resection margin; CT, computed tomography; EUS, endoscopic ultrasonography; MRI, magnetic resonance imaging; RCT,
radiochemotherapy; SCRT, short course of radiotherapy; NICE, National Institute for Health and Care Excellence; RT, radiotherapy.
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There are also significant ‘late effects from pelvic
radiotherapy’ on anorectal, urinary and sexual func-
tion [17,38,39], unexplained late cardiac effects [17],
insufficiency fractures in the pelvis [40], and an
increased risk of secondary malignancies after 10 years
[20,21]dall of which need to be balanced against the
risk of local recurrence.
Some have, therefore, questioned the routine use of
both these approaches (RCT and SCRT).
Fluoropyrimidine-based RCT does not employ full
systemically active doses of chemotherapy and delays
the integration of ACT. Many current investigative ap-
proaches in rectal cancer take the view that better results
might be obtained by adding and/or extending more
intensive chemotherapy into the neoadjuvant setting.
The question is, whether radiotherapy is needed at all?
5. Neoadjuvant long-course RCT versus SCRT
The aims of neoadjuvant therapy in locally advanced
rectal cancer (LARC) are to decrease the risk of
locoregional relapse and to downsize/downstage tu-
mours that threaten the mesorectal fascia or to facilitate
sphincter preservation. Long-course RCT or SCRT is
currently used (Tables 4 and 5). In the latter, the original
protocol scheduled the operation for the week following
radiation therapy. More recently, protocols for delayed
surgery have been evaluated in clinical trials [41].
The consensus panel discussed the indications for
RCT and SCRT in various clinical situations. Rectal
cancers localised in the upper third of the rectum were
exempt from the discussion as they are usually treated
similarly to colon cancer.
For easily resectable rectal cancer of the mid-rectum
with no detectable lymph node metastases (cT3 cN0), an
equal number of panellists favoured either option, if a
combined therapy was indicated. In the trials directly
comparing SCRT and RCT [19,42], LR rates were
similar and 75% of the panellists considered SCRT to be
acceptable in this situation. As discussed above, the
indication for preoperative therapy in this group of
patients has been questioned since the introduction of
TME has significantly reduced the rate of LR.
However, more than half of the panellists considered
RCT the best option for cancer of the mid-rectum with
lymph node metastases (cT3 cNþ) even when it was
easily resectable, with only very few voting against any
neoadjuvant treatment. Both the Dutch and the MRC
trials [23,24] show a significant decrease of LR in node-
positive tumours in the TME era. However, analysis of
the surgical specimen quality in the CR07 trial has also
shown that pelvic recurrence rates were 20% for poor-
grade TME compared with only 6% for good-quality
CRM-negative TME node-positive patients which
compared favourably with 5% local recurrence rates in
node-negative patients in good-grade TME specimens
[37]. Approximately 18% of audited TME specimens in
the Dutch TME trial were poor grade and preoperative
CRM status had not been assessed in either CR07 or
Dutch TME trials. Therefore, a neoadjuvant approach
seems indicated in node-positive disease if the quality of
the TME surgery is in doubt and preoperative assess-
ment of the MRI-validated prognostic factors linked to
local recurrence, i.e. mrCRM, mrT substage and
mrEMVI, is not established.
For rectal cancer situated in the ‘low rectum’
(without lymph node metastases), three quarters of the
panellists favoured RCT and only one quarter consid-
ered SCRT the best option. The risk for LR for tumours
in the low rectum even in the TME era and after neo-
adjuvant therapy is relatively high (10.1% LR in the
German trial) [43]. Implementation of an MRI-based
low rectal cancer staging classification enables identifi-
cation of patients for primary surgery with a 98% clear
margin rate in just under half of the patients presenting
with low-risk rectal cancers at <6 cm from the anal
verge. Preoperative therapy of high-risk MR low rectal
cancer tumours followed by a good mrTRG and
regression of tumour from the intersphincteric plane
results in 0% pCRM rates. A poor response necessitates
the use of a beyond TME approach in order to achieve
clear margins either by extralevator APE or in some
cases exenterative surgery [44].
The role of SCRT was first established in the 1990s by
a series of randomised trials [45e47] in resectable and
early rectal cancers with the aim of reducing the risk of
Table 4
Comparison of treatment and performance characteristics of SCRT or RCT for rectal cancer.
SCRT Short-course radiotherapy RCT Long-course radiochemotherapy
Total radiation dose 25 Gy 45e50.4 Gy
Fraction size/number 5 Gy in five fractions 1.8e2 Gy in 23e28 fractions
Radiation duration 1 week 5e5.5 weeks
BED, acute effects 37.5 Gy 37.5e44.4 Gy
BED, late effects 66.7 72e84 Gy
Overall time to surgery 10 d 10e14 weeks
Concomitant chemotherapy No Yes
Acute toxicity Minimal if immediate surgery 10e24% G3
Late toxicity G3/G4 8e10% G3/G4 8e10%
Downsizing/downstaging No (unless surgery delayed) Yes
BED, biologically effective dose; RCT, radiochemotherapy; SCRT, short course of radiotherapy.
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Table 5
Summary results of randomised radiotherapy trials in rectal cancer.
Treatment arms TME Stages Adjuvant
chemotherapy
LR (5 years) DR (5 years) OS (5 years) Remarks
Trials with RCT (long-course RCT)
EORTC 22921 [51], NZ 1011 25  1.8 Gy
25  1.8 Gy/preop 5FU
25  1.8 Gy/postop 5FU
25  1.8 Gy/preop
þ postop
n.a. IIeIII 4 Cycles 5FU/LV
(depending on
treatment arm)
21.9%
10.9%
13.7%
10.7%
36.9%
32.1%
33.5%
29.8%
No significant
difference at
10 years
Bolus 5FU/LV with
radiotherapy (depending
on treatment arm)
FFCD 92032 [27],
NZ 733
25  1.8 Gy
25  1.8 Gy/bolus 5FU
Rec. IIeIII 4 Cycles 5FU/LV 16.5%
8.1%
19.3%
24.3%
67.9%
67.4%
Bolus 5FU/LV with
radiotherapy
NSABP R-03 [28],
NZ 267
Preop 28  1.8
Gy/5FU
Postop 28  1.8
Gy/5FU
n.a. IIeIII 5 Cycles 5FU/LV 10.7%
10.7%
n.a. 74.5%
65.6%
Bolus 5FU/LV with
radiotherapy
CAO/ARO/AIO-94
Trial [43], NZ 823
Preop 28  1.8
Gy/5FU
Postop 28  1.8
Gy/5FU
Yes IIeIII 4 Cycles 5FU/LV 5.0%
9.7%
29.8% (10 years)
29.6%
59.6% (10 years)
59.9%
CIV 5FU with
radiotherapy
Trials with SCRT (short-course radiotherapy)
Swedish Rectal
Cancer Trial [45], NZ 1168
None
5  5 Gy
No IeIII No 26% (13 years)
9%
34% (13 years)
34%
30% (13 years)
38%
Equal effects for
mid and low rectum
Dutch Colorectal
Cancer [46] Group
Trial 2, NZ 1861
None
5  5 Gy
Yes IeIII
(eIV)
No 10.9%
5.6%
28.3%
25.8%
63.5%
64.2%
Little effect for high
and low rectum
MRC CR-07/NCIC-
CTG C016 [24]
NZ 1350
5  5 Gy
(postop 25  1.8
Gy, 5FU)
Rec. IeIII According to
local policy
4.7%
11.5%
19%
21%
70.3%
67.9%
Postop. RCT for
involved circumferential
margin only
Polish Rectal Cancer
Trial [19], NZ 312
5  5 Gy
28  1.8 Gy,
bolus 5FU
Yes T3/4 N0-2 Optional 9.0% (4 years)
14.2%
31.4% (4 years)
34.6%
67.2% (4 years)
66.2%
Trans-Tasman Trial
01.04 [42], NZ 326
5  5 Gy
28  1.8 Gy,
5FU CIV
Yes T3 N0-2 Mandated
FUFA 6/12
7.5% (3 years)
4.4%
27%
30%
74%
70%
Imbalance regarding
location of primary
Pach et al. [77],
NZ 154
5  5 Gy surgery
7e10 d
5  5 Gy surgery
4e5 weeks
n.a. IeIII Not stated 1.5% 7% 63%
73%
Delayed surgery may
require longer interval
EORTC, European Organisation for Research and Treatment of Cancer; n.a., not applicable; TME, percentage of patients treated with total mesorectal excision; LR, local recurrence; DR, distal
recurrence; OS, overall survival; preop, preoperative; postop, postoperative; RCT, radiochemotherapy; Rec., recommended; FFCD, Fe´de´ration Francophone de Cance´rologie Digestive; NSABP,
National Adjuvant Breast and Bowel Project; CAO/ARO/AIO, Chirurgische Arbeitsgemeinschaft Onkologie/Arbeitsgemeinschaft Radioonkologie/Arbeitsgemeinschaft Internistische Onkologie;
MRC, Medical Research Council; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group; LV, leucovorin; 5FU, 5-fluorouracil.
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local recurrence, which was 20e30% after surgery alone,
reflecting the suboptimal surgical practice at that time.
Two subsequent, more modern trials early in the
TME era, addressed the key question: did SCRT simply
compensate for poor surgical technique? These trials
tested whether SCRT still reduced local recurrence even
if TME was performed [24,46]. In the control group,
postoperative radiotherapy or RCT was intended to be
given in the event of a histopathological positive CRM
in the Dutch TME study and the CR07 trial, respec-
tively. Both trials demonstrated a reduction in local
recurrence, but overall survival was not improved, and
the risk of metastases predominated over local recur-
rence [21,24,37,46].
The second radiation option is combined RCT with
daily radiation fractions of 1.8 e 2.0 Gy up to a total
dose of 45 e 50 Gy. Concurrently, a fluoropyrimidine-
based chemotherapy is given, most often infusional 5-
fluorouracil (5FU) or capecitabine, which has been
extrapolated from the successful strategy of post-
operative 5FU-based RCT for patients with stage II or
III rectal cancer. Several groups performed randomised
trials of preoperative 5FU-based RCT and demon-
strated an improvement in locoregional control [25e27]
but this did not translate into an improvement in DFS
or OS. Only in more advanced unresectable or border-
line resectable cases did RCT result in improved
resectability and DFS [22].
With the increased accuracy of preoperative imaging
to define the potential for curative resection, RCT has
been taken up more widely, particularly when the CRM
is predicted to be compromised. In contrast, SCRT and
immediate surgery is primarily not intended to achieve
significant shrinkage or pathological downstaging. The
Dutch TME trial found no significant difference in
TNM stage distribution between SCRT and surgery-
alone groups [46], but T-stage downstaging was
observed if surgery was delayed for more than 10
d following the completion of SCRT [48]. Further
extension of the interval following SCRT to surgery of
at least 6 weeks does demonstrate more downstaging,
but the optimal interval has not been defined [41,49].
Whether the same degree of tumour shrinkage to that
seen with RCT can be achieved with SCRT and an
extended interval to surgery is currently unclear. Recent
preliminary data from a Polish trial comparing two
neoadjuvant treatment protocols (SCRT followed by
4  FOLFOX4 or RCT with bolus 5FU/leucovorin
(LV) and oxaliplatin) resulted in comparable local effi-
cacy and possibly improved overall survival with SCRT
(ASCO GI 2016, Abstract # 489).
Overall, the consensuspanel recommended long-course
RCT over short-course radiotherapy for most clinical
situations in which neoadjuvant treatment is indicated,
with the exception of T3a/b N0 tumours with clear mes-
orectal fascia (>1 mm) where short-course radiotherapy
or no therapy were regarded to be equivalent.
6. Adjuvant chemotherapy
Most cancer-related deaths in patients with rectal cancer
are due to distant metastases. ACT in colon cancer re-
duces the incidence of distant relapse and improves
overall survival. In analogy, ACT was integrated into
postoperative and perioperative treatment strategies in
rectal cancer. However, although ACT after preopera-
tive RCT and surgery is currently recommended in most
guidelines [50], the contribution of the adjuvant part to
the benefit of the perioperative therapy had not been
formally tested in a randomised trial at the time of the
St. Gallen 2014 consensus meeting. The first indication
that ACT may not improve local or distant relapse rate
after preoperative RCT came from the EORTC 22921
trial [51] and was further questioned in other trials
[52e54] (see Table 6).
At the consensus session, most panellists (83%) rec-
ommended against ACT for cN0/ypN0 tumours.
However, for tumours that were initially lymph node
positive but became lymph node negative after RCT
(i.e. cNþ/ypN0), the panellists’ opinion on ACT was
divided (pro 41%, con 59%). In cases with histologically
confirmed positive lymph nodes after neoadjuvant RCT
Table 6
Adjuvant chemotherapy trials in rectal cancer and meta-analysis.
Treatment Arms Stages DFS OS Remarks
EORTC 22921 [51]
NZ 1011
Follow-up
5FU/LV
IIeIII 47%
43.7%
51.8%
48.4%
At 10 years
Chronicle [52]
NZ 113
Follow-up
Xelox
IeIII 71.3%
77.5%
87.8%
88.8%
At 3 years
I-CNR-RT [54]
NZ 655
Follow-up
5FU/LV
IIeIII 62.8%
65.3%
70%
69.1%
At 5 years
PROCTOR/SCRIPT [53]
NZ 823
Follow-up
5FU/LV or cape
IIeIII 55.4%
62.7%
79.2%
80.4%
At 5 years
Meta-analysis [55]
NZ 1196
Follow-up
Adjuvant chemotherapy
IIeIII HR 0.91
(0.77e1.07)
HR 0.97
(0.81e1.17)
10e15 cm from anal verge
HR for DFS 0.59 (0.40e0.85)
cape, capecitabine; DFS, disease-free survival; EORTC, European Organisation for Research and Treatment of Cancer; HR, hazard ratio; OS,
overall survival.
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(ypNþ), the majority of panellists (77%) voted in favour
of ACT.
About half the panellists (47%) were in favour of
ACT that included oxaliplatin with 16% against this
option. When ACT is indicated, most panellists (68%)
agreed that a colostomy should be closed after
completion of chemotherapy to avoid an interruption
that might mitigate the effect of the ACT.
After the consensus meeting, results from a number of
clinical trials investigating the role of ACT in this situa-
tion were published (Table 6). Since these results have the
potential to change clinical practice, we compiled the ev-
idence in a table without additional panel voting. These
new data do not support the further use of ACT as a
standard in mid and low rectal cancer (less than 10 cm
from the anal verge) after neoadjuvant RCT and R0
resection, irrespective of T stage and nodal status [55].
However, for upper rectal cancer between 10 and 15 cm
from the anal verge, ACT can be considered as standard
for lymph nodeepositive tumours (either cNþ before
neoadjuvant therapy and/or ypNþ) [55]. This regimen
should usually include oxaliplatin (panel: 47% yes, 16%
no, 37% abstain), which is supported by data from colon
cancer and from a phase II trial in rectal cancer [56].
7. Clinical complete response after preoperative long-
course RCT
After RCT, some patients experience a complete clinical
response of their tumour. Managing these patients
without immediate surgery, but with frequent surveil-
lance presents an option that may obviate the need for a
surgical intervention for some of them [57]. To test the
limits of this strategy, the panellists were asked whether
this ‘watch and wait’ strategy was also justified in lymph
nodeepositive, low rectal cancer. In this situation, the
panel was equally divided for and against. Half of the
panellists were in favour of ‘adjuvant’ chemotherapy
after achieving a complete clinical response by RCT
provided careful follow up was feasible, thus avoiding a
primary operation. We did not ask if local excision with
organ preservation was also considered as an option.
8. Rectal cancer with synchronous liver metastases
The incidence of synchronous liver metastases in pa-
tients with primary rectal cancer is approximately 15%
[58]. The principle treatment goal is complete resection
of all primary and metastatic lesions with a curative
approach, but the choice and sequence of the available
treatment modalities depend on the clinical situation.
Patients can grossly be divided into two groups: those
with initially resectable and potentially resectable dis-
ease after conversion therapy and those patients in
whom complete resection of the primary tumour or the
metastases will not be achievable.
In patients with ‘unresectable metastatic rectal can-
cer’, the primary treatment goal is maintaining quality
of life, improving tumour-related symptoms and mini-
mising treatment-related side-effects. Accordingly, if the
primary tumour was not going to be removed, the panel
voted against pelvic radiotherapy in patients with an
asymptomatic rectal tumour and synchronous liver
metastases (79% no) and also against local ablative
treatment by surgery or radiologic intervention even if
the hepatic lesions were small and few (80% no).
Reported mortality after resection of the primary
tumour in patients with incurable stage IV colorectal
cancer ranges from 1.3% to 16%, which is significantly
higher than resection for colorectal cancer in general
[59,60]. For this reason, there is a tendency towards a
conservative approach, especially in asymptomatic pa-
tients. A deviating loop colostomy (preferably by lapa-
roscopy) is often an effective alternative. Palliative
pelvic radiotherapy was analysed in a systematic review
by Cameron et al. [62] and showed a pooled overall
symptom response rate of 75%, although toxicity results
were not available [61]. SCRT with chemotherapy has
even been shown to spare palliative surgery in 80% of
symptomatic patients in a phase II trial. A stent can be
placed to treat obstructing rectal cancer, but endoscopic
stenting options for low-lying rectal tumours are limited
and may cause significant side-effects. A randomised
study by Fiori et al. [63] analysed 22 patients with stage
IV unresectable rectosigmoid cancer with symptoms of
subacute obstruction. Patients were treated by either
endoscopic placement of an expandable stent or
diverting proximal colostomy and were followed until
death. There were no differences between treatment-
related morbidity or mortality, but hospital stay and
restoration of oral feeding and bowel function were
shorter after stenting.
In ‘potentially resectable disease’, treatment of the
primary rectal tumour per se consists of surgery after
SCRT or RCT. Most patients with synchronous liver
metastases present with advanced rectal disease and, thus,
formally have an indication for prior RCT [64]. However,
standard RCT based on a fluoropyrimidine-alone
chemotherapy backbone likely results in under-treatment
of the metastatic disease for a substantial time interval
which may be further prolonged by postoperative com-
plications if the rectal tumour is removed first. Therefore,
the panel did not see an indication to start with
fluoropyrimidine-based RCT in these patients (83% no).
As SCRT and delayed (4e8 weeks) rectal surgery in
resectable cancers can result in local tumour regression
in 74% of patients and has a low-toxicity profile [65], it
may offer both local control and, more importantly, the
opportunity to start systemic therapy almost instantly,
optimising the treatment of metastatic disease. The
feasibility of such an approach has been demonstrated
in a phase II trial, where SCRT was followed by cape-
citabine, oxaliplatin, and bevacizumab for up to six
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cycles and surgery 6e8 weeks after the last cycle [66].
Radical R0 surgery of all tumour sites was possible in 36
of 50 (72%) patients. An interim analysis of a rando-
mised trial in patients with fixed cT3 or cT4 or locally
recurrent rectal cancer showed this strategy
(SCRT þ FOLFOX) achieved a microscopically radical
resection (primary end-point) in 73% [67].
‘Systemic therapy alone’ can also induce significant
response of the tumour. A case series of 22 patients with
rectal cancer demonstrated an objective pathological
response in 12 patients, including one patient with a
complete response [68]. Prior to the start of treatment,
symptomatic rectal tumours with clinical signs of
obstruction should be decompressed with a colostomy to
avoid treatment delays for emergency intervention.
However, in patients with an endoscopically obstructing
tumour only (with no clinical symptoms or signs of
obstruction), a diversion colostomy seems not needed.
Patel et al. [69] showed progression to complete obstruc-
tion needing surgery in only 2 of 85 patients during neo-
adjuvant systemic therapy in patients with endoscopically
obstructing rectal tumours. As to the panel, all members
elected combination regimens for initial treatment.
Traditionally, the strategy for surgical management
of colorectal carcinoma with resectable liver metastases
was resection of the primary tumour followed by treat-
ment of the liver metastases, with or without perioper-
ative systemic therapy. This approach has been
challenged by a ‘liver-first approach’ because the prog-
nosis is usually related to the liver metastases. Further-
more, the liver-first approach has a higher percentage of
patients completing the full treatment protocol and it
avoids delay due to complications of rectal surgery [70].
The St. Gallen panel saw a place for the primary
resection of a small resectable liver lesion before the
start of RCT for LARC (52% yes versus 43% no).
In a systematic review of patients with colorectal
tumours, the common treatment sequence in four
studies comprised neoadjuvant systemic chemotherapy,
liver resection, RCT for the rectal tumours, followed by
colorectal resection and ACT; 90 of the 121 (74%) pa-
tients in this review completed the full treatment pro-
tocol and disease progression occurred in 23 patients
(19%). In the study describing patients with rectal
cancer only, 73% (16 of 22) completed the full protocol
with a 5-year survival rate of 67% and a median pro-
gression-free survival of 19 months [71]. Another
argument to choose a liver-first strategy in patients with
synchronous rectal cancer is the chance of a complete
response of the primary tumour after chemoradiation
of 15e25% and, thus, the possibility of a wait-and-see
policy [72]. Synchronous resection has been proposed
as an alternative approach with less abdominal in-
terventions, but this approach has not been compared
to others in a randomised trial [73]. An important
factor seems to be patient selection by an experienced
multidisciplinary team.
In summary, optimised MRI with standardised pro-
tocols or MRI þ EUS were considered as corner stones
of pretherapeutic imaging. Early tumours with limited
risk of recurrence were considered as candidates for
primary surgery whereas all others should receive
multimodal treatment. In general, long-course RCT was
preferred over short-course radiotherapy, if neoadjuvant
treatment is indicated. In patients with resectable syn-
chronous liver metastases, a treatment strategy with
optimum systemic chemotherapy supported by short-
course radiotherapy of the primary tumour was the
favoured approach.
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